Chinanews client, Beijing, March 28 (Reporter Zhang Ni) According to the latest data from the National Health Commission, as of 24:00 on the 27th, more than 100 million doses of new crown virus vaccine have been reported nationwide.
While vaccination work is advancing steadily across the country, issues such as "how long is the vaccine protection period" and "whether to continue after the two injections" have also become the focus of public attention in the near future.
At the press conference held on the 28th of the Joint Prevention and Control Mechanism of the State Council, a series of public opinion concerns were responded to.
On March 27th, students from Peking University were vaccinated against the new crown at the Qiu Deba Gymnasium.
Photo by China News Agency reporter Tian Yuhao
About the vaccine protection period
——There is still a certain level of antibodies in the new crown vaccination for 9 months
At present, many people in China have been vaccinated against the new crown vaccine. One of the questions that everyone is most concerned about is: How long is the protection period of the vaccine?
"Everyone knows that the new coronavirus vaccine is a new vaccine. It has been developed in a relatively short period of time and has been used in humans for a shorter period of time. The current antibody level monitoring is about six months or more." Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention Introduced at the press conference.
According to Zhang Yuntao, vice president of Sinopharm China Biotechnology, in March last year, some people as the vaccine "vanguard" have been vaccinated with the now-marketed inactivated new crown vaccine.
Through continuous testing of their antibody change data, 9 months of antibody testing data have been obtained so far.
From the data point of view, there is still a certain level of antibody at 9 months.
However, Wang Huaqing emphasized that antibodies are not the only indicator of protection. There are other factors that play a role in the process of vaccines. Therefore, follow-up studies on the durability of vaccines are needed to determine how long its protection period is.
On March 27th, students from Peking University were vaccinated against the new crown at the Qiu Deba Gymnasium.
Photo by China News Agency reporter Tian Yuhao
About vaccination booster
——The booster needle for the new crown vaccine has been designed
People who have been vaccinated against the new crown need to be vaccinated again in the future?
Regarding this issue, a key message was revealed at the press conference on the 28th: the booster needle for the new crown vaccine has been designed.
"In the clinical process of our overall design, we designed a booster vaccination to observe the level of antibody persistence and protection. According to the preliminary results obtained, the booster can effectively increase the titer of neutralizing antibodies and effectively enhance the durability of the antibody. It can effectively improve the vaccine's ability to resist mutation."
Zhang Yuntao emphasized that in the future, three phase clinical studies of vaccines will be carried out overseas to continuously observe antibody persistence and protection persistence.
Do I need to be inoculated with booster shots?
When will you come to fight?
These questions will be answered based on the results of the next three phases of clinical research.
Data map: Medical staff are preparing vaccines.
Photo by China News Agency reporter Hou Yu
About virus mutation
——Continue to promote the research and development of mutant vaccines
The mutation of the new crown virus has always received great attention at home and abroad.
So, are Chinese vaccine companies prepared to deal with it?
"We are continuing to advance the research and development of variant vaccines."
Zhang Yuntao said that small virus mutations will not affect the antigenicity of the vaccine, that is to say, the vaccine will be effective without the protective antigen mutation, especially the whole virus inactivated vaccine.
He emphasized that Sinopharm Sinobio has rich experience in vaccine research and development. Even in the case of major mutations in the new coronavirus, it can respond quickly and effectively under the rapid processing guidance of the National Vaccine Team, the Food and Drug Administration and other relevant departments. In response, the research and development of vaccines for related variant strains is currently being actively promoted.
Gao Qiang, general manager of Beijing Kexing Zhongwei Biotechnology Company, also responded that Kexing Zhongwei's new crown inactivated vaccine process is very mature and can be used as a model vaccine.
In theory, changing the strain does not need to change the process route or process quality standards. The feasibility is good, and small-scale tests are needed to determine whether the existing process routes can fully reproduce the vaccine quality standards and processes.
Gao Qiang said that if it can be reproduced, small-scale clinical trials can be used to further confirm the response of the vaccine in humans. If there is a response, the replaced strain can be used for vaccine production to further prevent the mutant strain from infecting humans.
Data map: New coronavirus inactivated vaccine sample.
Photo by Zhang Qin
About remote inoculation and replanting
——Try to use the same enterprise variety to complete two doses of inoculation
As the domestic epidemic has stabilized, the flow of people has gradually increased, and there have been more and more business trips and migrant workers. Many people are facing the problem of a second shot of vaccination in different places.
In this regard, Wang Huaqing said at the press conference that the "New Coronavirus Vaccination Technical Guide" has relevant regulations. It is recommended to use the same company’s varieties to complete two doses of inoculation. If the same varieties are not available in different places, the same varieties can be used. Vaccine products of other production units of different types were replaced, and two doses of vaccination were completed.
In addition, for some people who did not get the second shot within the recommended time due to various reasons, Wang Huaqing said that if the first shot was vaccinated, the second shot was not completed within the prescribed time, and there is no need for the subsequent second shot to reseed. Restart the vaccination, as long as the second vaccination is completed.
Data map: On March 18, a 66-year-old man registered his personal information at the vaccination site of Jianguomen Street Sports Center.
Photo by China News Agency reporter Jia Tianyong
About "one old and one young" vaccination
-Actively and steadily promote vaccination for people over 60 years old
At present, the main targets of domestic COVID-19 vaccination are people aged 18-59, as well as healthy elderly people over 60 years old in need.
The public is also concerned about when the "one old and one small" vaccination will be fully implemented.
According to Wu Liangyou, deputy director of the National Health Commission’s Disease Control Bureau, Beijing, Shanghai and other regions are currently in accordance with the unified national deployment, and under the premise of fully assessing the health status of the vaccinated subjects and the risk of infection, they have been Elderly people over 60 years old and patients with chronic diseases who have a better basic condition have been vaccinated against the new coronavirus.
The next step will be to actively and steadily promote the vaccination of people over 60 years old and patients with chronic diseases in combination with the effect of vaccines in large-scale populations.
As for people under the age of 18, Wang Huaqing said at the meeting that there is no systematic Phase III clinical data yet.
These data will be obtained in the future as the research progresses.
So when will vaccination be carried out for people under the age of 18?
From the perspective of the country as a whole, there are considerations, and the vaccination strategy will be continuously improved based on the needs of epidemic prevention and control and clinical data, which also includes the newborn population.
(Finish)